Figure 5.
Effects of carfilzomib (Cfz), UK101, and UK102 on cell viability of primary MM samples from 14 different donors, six from Btz/Cfz-naïve patients and eight from patients relapsed on Btz therapy. Primary MM cells were treated with Cfz (A, 50 nM), UK101 (B, 10 μM), or UK102 (C, 10 μM) for 48 h. Cell viability was measured using an ATP-based luminescent assay.